|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005953,
umls-concept:C0008976,
umls-concept:C0009647,
umls-concept:C0013018,
umls-concept:C0040732,
umls-concept:C0162371,
umls-concept:C0205173,
umls-concept:C0205390,
umls-concept:C0392756,
umls-concept:C0439849,
umls-concept:C0445223,
umls-concept:C0445356,
umls-concept:C0522510,
umls-concept:C1274040,
umls-concept:C1523987,
umls-concept:C1527362,
umls-concept:C1552599,
umls-concept:C1704787,
umls-concept:C2348042
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-7-15
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The Blood and Marrow Transplant Clinical Trials Network conducted 2 parallel multicenter phase 2 trials for individuals with leukemia or lymphoma and no suitable related donor. Reduced intensity conditioning (RIC) was used with either unrelated double umbilical cord blood (dUCB) or HLA-haploidentical related donor bone marrow (Haplo-marrow) transplantation. For both trials, the transplantation conditioning regimen incorporated cyclophosphamide, fludarabine, and 200 cGy of total body irradiation. The 1-year probabilities of overall and progression-free survival were 54% and 46%, respectively, after dUCB transplantation (n = 50) and 62% and 48%, respectively, after Haplo-marrow transplantation (n = 50). The day +56 cumulative incidence of neutrophil recovery was 94% after dUCB and 96% after Haplo-marrow transplantation. The 100-day cumulative incidence of grade II-IV acute GVHD was 40% after dUCB and 32% after Haplo-marrow transplantation. The 1-year cumulative incidences of nonrelapse mortality and relapse after dUCB transplantation were 24% and 31%, respectively, with corresponding results of 7% and 45%, respectively, after Haplo-marrow transplantation. These multicenter studies confirm the utility of dUCB and Haplo-marrow as alternative donor sources and set the stage for a multicenter randomized clinical trial to assess the relative efficacy of these 2 strategies. The trials are registered at www.clinicaltrials.gov under NCT00864227 (BMT CTN 0604) and NCT00849147 (BMT CTN 0603).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:AljitawiOmar SOS,
pubmed-author:BallenKaren KKK,
pubmed-author:Blood and Marrow Transplant Clinical Trials Network,
pubmed-author:BrunsteinClaudio GCG,
pubmed-author:CarterShelly LSL,
pubmed-author:CostaLuciano JLJ,
pubmed-author:CutlerCorey SCS,
pubmed-author:DevineSteven MSM,
pubmed-author:EapenMaryM,
pubmed-author:FuchsEphraim JEJ,
pubmed-author:JagasiaMadan HMH,
pubmed-author:KaranesChatchadaC,
pubmed-author:O'DonnellPaul VPV,
pubmed-author:WingardJohn RJR,
pubmed-author:WuJuanJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
14
|
|
pubmed:volume |
118
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
282-8
|
|
pubmed:meshHeading |
pubmed-meshheading:21527516-Adolescent,
pubmed-meshheading:21527516-Adult,
pubmed-meshheading:21527516-Aged,
pubmed-meshheading:21527516-Algorithms,
pubmed-meshheading:21527516-Bone Marrow Transplantation,
pubmed-meshheading:21527516-Child,
pubmed-meshheading:21527516-Family,
pubmed-meshheading:21527516-Female,
pubmed-meshheading:21527516-Fetal Blood,
pubmed-meshheading:21527516-Graft Survival,
pubmed-meshheading:21527516-HLA Antigens,
pubmed-meshheading:21527516-Hematologic Neoplasms,
pubmed-meshheading:21527516-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:21527516-Histocompatibility Testing,
pubmed-meshheading:21527516-Humans,
pubmed-meshheading:21527516-Male,
pubmed-meshheading:21527516-Middle Aged,
pubmed-meshheading:21527516-Survival Analysis,
pubmed-meshheading:21527516-Tissue Donors,
pubmed-meshheading:21527516-Transplantation, Homologous,
pubmed-meshheading:21527516-Transplantation Conditioning,
pubmed-meshheading:21527516-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.
|
|
pubmed:affiliation |
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA. bruns072@umn.edu
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
